[go: up one dir, main page]

CN109476677A - 抗hcmv病毒化合物 - Google Patents

抗hcmv病毒化合物 Download PDF

Info

Publication number
CN109476677A
CN109476677A CN201780045987.0A CN201780045987A CN109476677A CN 109476677 A CN109476677 A CN 109476677A CN 201780045987 A CN201780045987 A CN 201780045987A CN 109476677 A CN109476677 A CN 109476677A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
tautomer
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780045987.0A
Other languages
English (en)
Other versions
CN109476677B (zh
Inventor
熊剑
王晶晶
伍文韬
谭海忠
彭宣嘉
张杨
陈新海
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huinuo Biomedical Technology Hangzhou Co ltd
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN109476677A publication Critical patent/CN109476677A/zh
Application granted granted Critical
Publication of CN109476677B publication Critical patent/CN109476677B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

一类抗HCMV病毒的并环类化合物，及其在制备治疗与HCMV病毒相关疾病的药物中的应用。具体为式(Ⅱ)所示化合物及其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (44)

  1. PCT国内申请，权利要求书已公开。
CN201780045987.0A 2016-08-08 2017-08-08 抗hcmv病毒化合物 Active CN109476677B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016106440911 2016-08-08
CN201610644091 2016-08-08
PCT/CN2017/096366 WO2018028556A1 (zh) 2016-08-08 2017-08-08 抗hcmv病毒化合物

Publications (2)

Publication Number Publication Date
CN109476677A true CN109476677A (zh) 2019-03-15
CN109476677B CN109476677B (zh) 2024-06-07

Family

ID=61161770

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780045987.0A Active CN109476677B (zh) 2016-08-08 2017-08-08 抗hcmv病毒化合物

Country Status (6)

Country Link
US (1) US10851112B2 (zh)
EP (1) EP3498715B1 (zh)
JP (1) JP6951418B2 (zh)
CN (1) CN109476677B (zh)
ES (1) ES2882531T3 (zh)
WO (1) WO2018028556A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3753942B1 (en) * 2018-02-08 2024-01-03 Phaeno Therapeutics Co., Ltd. Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method therefor

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103917527A (zh) * 2011-09-16 2014-07-09 拜耳知识产权有限责任公司 取代的5-氟-嘧啶
WO2015043364A1 (zh) * 2013-09-29 2015-04-02 华北制药集团新药研究开发有限责任公司 作为凝血因子Xa抑制剂的苯并恶唑并恶嗪酮类化合物
CN104693211A (zh) * 2013-12-10 2015-06-10 南京明德新药研发股份有限公司 作为抗病毒剂的咪唑衍生物及其制药用途
CN104860935A (zh) * 2014-02-21 2015-08-26 常州寅盛药业有限公司 作为丙肝病毒抑制剂的噻吩或其变体衍生物及其制药用途
US20160016975A1 (en) * 2013-03-15 2016-01-21 Merck Sharp & Dohme Corp. C2-azaspiro iminothiazine dioxides as bace inhibitors, compositions, and their use
CN105793265A (zh) * 2013-12-10 2016-07-20 南京明德新药研发股份有限公司 作为抗病毒剂的咪唑衍生物及其制药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) * 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE102004022672A1 (de) * 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
WO2016109360A1 (en) * 2014-12-29 2016-07-07 Auspex Pharmaceuticals, Inc. Dihydroquinazoline inhibitors of viral terminase

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103917527A (zh) * 2011-09-16 2014-07-09 拜耳知识产权有限责任公司 取代的5-氟-嘧啶
US20160016975A1 (en) * 2013-03-15 2016-01-21 Merck Sharp & Dohme Corp. C2-azaspiro iminothiazine dioxides as bace inhibitors, compositions, and their use
WO2015043364A1 (zh) * 2013-09-29 2015-04-02 华北制药集团新药研究开发有限责任公司 作为凝血因子Xa抑制剂的苯并恶唑并恶嗪酮类化合物
CN104693211A (zh) * 2013-12-10 2015-06-10 南京明德新药研发股份有限公司 作为抗病毒剂的咪唑衍生物及其制药用途
CN105793265A (zh) * 2013-12-10 2016-07-20 南京明德新药研发股份有限公司 作为抗病毒剂的咪唑衍生物及其制药用途
CN104860935A (zh) * 2014-02-21 2015-08-26 常州寅盛药业有限公司 作为丙肝病毒抑制剂的噻吩或其变体衍生物及其制药用途

Also Published As

Publication number Publication date
JP2019524810A (ja) 2019-09-05
EP3498715B1 (en) 2021-06-09
US10851112B2 (en) 2020-12-01
JP6951418B2 (ja) 2021-10-20
ES2882531T3 (es) 2021-12-02
EP3498715A4 (en) 2019-06-26
US20190202838A1 (en) 2019-07-04
WO2018028556A1 (zh) 2018-02-15
EP3498715A1 (en) 2019-06-19
CN109476677B (zh) 2024-06-07

Similar Documents

Publication Publication Date Title
CN109311859A (zh) 用于治疗纤维化和炎性疾病的含杂原子环丁烷取代基的吡啶酮衍生物
CN109311812A (zh) 作为c-MET抑制剂的吡啶酮类化合物
CN110248926A (zh) Lsd1抑制剂及其制备方法和应用
CN111757878A (zh) 一种哒嗪类衍生物抑制剂、其制备方法和应用
JP2008543886A5 (zh)
HRP20230737T1 (hr) 4-metilsulfonil-supstituirani spojevi piperidin uree korisni za liječenje srčanih poremećaja kao što je dilatirana kardiomiopatija (dcm)
JP2013537203A5 (zh)
CN110139865A (zh) Fgfr抑制剂
JP2019510082A5 (zh)
JP2016505637A5 (zh)
JP2017501237A5 (zh)
CN110382463A (zh) Hdac6选择性抑制剂及其制备方法和应用
CN110546150A (zh) 含吡唑基的三并环类衍生物、其制备方法和应用
EA201692129A1 (ru) Диаминотриазины в качестве гербицидов
CN109415341A (zh) 作为TGF-βR1抑制剂的苯并三氮唑衍生的α，β不饱和酰胺类化合物
JP2016540028A5 (zh)
JP2017506248A5 (zh)
JP2013540712A5 (zh)
CN109689652A (zh) 稠杂环类衍生物、其制备方法及其在医学上的应用
CN115315423A (zh) 取代芳基类化合物
CN111566100A (zh) 嘧啶类化合物、其制备方法及其医药用途
CN110709402A (zh) 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途
RU2018122224A (ru) Фармацевтическая композиция для лечения или предупреждения nash
MX2017005060A (es) Compuestos atropisomeros triciclicos.
CN111770754A (zh) 一种多环类衍生物调节剂、其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 210032 room 218, business office, building 9, Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant after: Nanjing Mingde New Drug Development Co.,Ltd.

Address before: Room 218, No. 9 Commercial Office Building, Gaoxin Road, Nanjing High-tech Development Zone, Jiangsu Province

Applicant before: MEDSHINE DISCOVERY Inc.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20211221

Address after: 310018 room 1-404, Heda Medicine Valley Center, 291 Fucheng Road, Xiasha street, Hangzhou Economic and Technological Development Zone, Zhejiang Province

Applicant after: Huinuo biomedical technology (Hangzhou) Co.,Ltd.

Address before: 210032 room 218, business office, building 9, Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment